Introduction:
The maintenance of corneal transparency is required for optimal vision. Accordingly the tissue must preserve avascularity and alymphaticity. 1 Multiple pathological conditions lead to angiogenesis and lymphangiogenesis in the cornea. 2, 3 The VEGF family of molecules dominates the blood 4 and lymphatic 5 vessel growth signaling landscape. While the cornea expresses several inhibitors of hemangiogenesis (soluble FLT-1 6 , thrombospondins 7 , endostatin 8 , and pigment epithelium derived factor 9 , among other factors 10 ), few inhibitors of lymphangiogenesis have been reported. 11 Blockade of lymphangiogenesis is of particular interest as its excessive expression enables corneal transplant rejection. 12 In adults, VEGFR-3 is expressed in the lymphatic endothelium and corneal epithelium. 13, 14 VEGF-C binds VEGFR-3, promoting lymphangiogenesis 15 , and contributing to physiological angiogenesis. 16 The VEGF-C propeptide undergoes stepwise proteolytic processing to generate ligands with increasing affinity for VEGFR-3, however, only the completely processed VEGF-C isoform appears to bind VEGFR-2. 17 Over-expression of VEGF-C in transgenic mice results in lymphatic endothelial cell hyperplasia and vessel enlargement. 18 VEGF-C is chemotactic for inflammatory cells secreting VEGF-A. 19 We have shown that soluble VEGFR-1 expressed in the cornea sequesters VEGF-A, controlling hemangiogenesis and maintaining corneal avascularity. 6 While previous studies have shown circulating serum forms of soluble VEGFR-3 can serve biomarkers in malignancy, 20, 21 an endogenous tissue-based soluble VEGFR-3, to our knowledge, has not been reported or characterized. In this study we show that soluble VEGFR-3 is expressed in the cornea and promotes alymphaticity by binding and sequestering VEGF-C, serving as a 'sink'; further it facilitates the avascularity of cornea by inhibiting VEGFR-2 phosphorylation effects of VEGF-C.
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Materials and Methods

Animals
3' RACE (Rapid Amplification of cDNA Ends)
A previously described 22 method was used to determine the 3' unique end of soluble VEGFR3. Human eyes were obtained from the Utah Lions Eye Bank. Total RNA was extracted from C57Bl/6J mouse and human cornea, using RNeasy Kit (Qiagen, Valencia, CA). 2ug of RNA was reverse transcribed using cDNA cloning primer (QT)
CCAGTGAGCAGAGTGACGAGGACTCGAGCTCAAGCTTTTTTTTTTTTTTTTT. cDNA was amplified using Q0 -CCAGTGAGCAGAGTGACG and VEGFR-3 domain 4 specific forward primer ATCAACAAACCTGACACGCTCCTG using a Long Range PCR Kit (Qiagen, Valencia, CA, USA), PCR conditions: 93ºC for 3minutes, 35 cycles of 93 ºC for 15 seconds, 55 ºC for 30 sec and 68 ºC for 5 minutes. PCR product was diluted 1: 50 and amplified again using
QI -GAGGACTCGAGCTCAAGC and VEGFR-3 domain 5 specific primer
For personal use only. on April 18, 2017 . by guest www.bloodjournal.org From CCAATCTCTTCGTCGTGCACATCA primers. PCR products were gel excised and the pcr 2.1 TOPO TA cloning kit (invitrogen) was used to clone the insert. The inserts were sequenced using M13 primers. Once the 3' end sequence of soluble VEGFR-3 was determined, the full length gene was cloned into pCMV Script vector using exon 1 and 3' end primers.
Corneal suturing and intrastromal injections
The recipient mice was anesthetized by intramuscular injection with ketamine (100mg/kg body weight) and xylazine (20mg/kg body weight). To dilate the pupil and anesthetize the cornea, 1% tropicamide ophthalmic solution and 0.5% proparacaine ophthalmic solution were used. Three symmetrical sutures were placed (11-0 nylon, CS160-6, ETHICON, INC). For plasmids, shRNA and siRNA injections under direct microscopic observation, a nick in the epithelium and anterior stroma of a Balb/c mouse cornea was made in the midperiphery with a 0.5-in., 30-gauge needle (BD Biosciences, Franklin Lakes, NJ). A 0.5-in., 33-gauge needle with a 30° bevel on a 10µL gas-tight syringe (Hamilton, Reno, NV) was introduced into the corneal stroma and advanced 1.5 mm to the corneal center. Two microliters of plasmid solutions (1 µg/µl) (pshRNA-sVEGFR-3, pshRNA-CTR, pshRNA-mVEGFR-3), (pCMV.sVEGFR-3 and pCMV.CTR) was injected into the stroma, to separate corneal lamellae and disperse the plasmid, as performed previously. 23 Antibodies (10µg) each, Anti VEGF-C antibody and isotype control goat IgG (Jackson Immunoresearch), were used for injections into mouse cornea as previously reported. 24 Eyes were harvested after 3, 5, and 10 day intervals for different downstream assays.
The efficiency of corneal transfection by naked plasmid exceeded 70%, as gauged by flow cytometry and X-gal staining as reported previously. 6 For personal use only. on April 18, 2017 . by guest www.bloodjournal.org From
Immunostaining and imaging
Eyes were harvested 10 days after injections. The corneas were fixed in acetone at room temperature for 20 minutes. After 4 washes in PBST (0.1% Tween20/PBS), the corneas were 
Corneal transplantation
Penetrating corneal transplantation was performed using previously described methods 25 using female mice (8 to 12 weeks old) of the BALB/c strain as graft recipients and mice of the C57BL/6 strain as graft donors (n=9-12 each group). The donor cornea was marked with a 2 mm trephine and the recipient cornea was marked with 1.5 mm trephine. The donor graft was sutured into the recipient bed using 6-8 10-0 nylon interrupted sutures. Sutures remained in the recipient's eye for one week after transplantation. Subconjunctival injection (15μl, 1μg/μl) of plasmids expressing sVEGFR3 and empty pCMV was performed on the day of keratoplasty and postoperatively at 1, 2, 3, and 4 weeks using a gas-tight syringe (Hamilton, Reno, NV, USA).
We monitored for graft rejection by a standardized opacity grading (0 to 5) system using previously described methods. [25] [26] [27] [28] Opacity grades 3 and above were considered a graft rejection.
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Results
Cloning and Characterization of sVEGFR-3
During the course of our studies we observed a smaller than expected band in western blot using an antibody specific to the N-terminus of VEGFR-3 (Supplemental Figure S1D) . We hypothesized this to be a truncated form of VEGFR-3. 3' RACE revealed a transcript of VEGFR-3 mRNA with exons 1 to 11 and retention of part of intron 11 ( Figure 1D ) lacking transmembrane and intracellular tyrosine kinase domains of VEGFR-3 ( Figure 1B) ; we designated the molecule soluble VEGFR-3 (sVEGFR-3 or sFLT-4). Cloning (Supplemental Figure S1A ) and sequencing (Supplemental Figure S1B) showed a sVEGFR-3 cDNA of 1575 bp in mouse and 1962 bp in human, encoding 59.5 kDa and 73.1 kDa proteins, respectively ( Figure   1C and Supplemental Figure S1D ). Mouse sVEGFR-3 has a 338 bp tail derived from intron 11 (Supplemental Figure S1B ). However, it contains an in-frame stop codon 24 bp downstream from the exon-intron 11 junction, which encodes 8 unique amino acids (Supplemental Figure   S1C ). Human sVEGFR-3 has a 414 bp unique intron-derived tail downstream from the exon-11/intron-11 junction, resulting in a unique C-terminal tail of 137 amino acids (Supplemental Figure S1B , C). A custom antibody (PA 4835 Thermo Scientific) was developed against this unique C-terminal tail of human sVEGFR-3 for further study.
Human and mouse cornea express soluble VEGFR-3 which binds VEGF-C sVEGFR-3 mRNA (Figure 2A ) and protein ( Figure 1C , 2B) were identified in the cornea, primarily in the epithelium ( Figure 2D and Supplemental Figure S2A ), and not in the sclera (Figure 2A, B) . Membrane VEGFR-3 was present in sclera ( Figure 2A , B) with minimal expression in cornea ( Figure 2A , C and Supplemental Figure S2B ). We confirmed VEGF-C mRNA and protein expression in cornea ( Figure 2E ).
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To see if sVEGFR-3 can bind to VEGF-C, as VEGFR-3 is known to bind VEGF-C 15 , in vivo interaction was confirmed by immunoprecipitation of corneal lysate with anti N-terminal VEGFR-3 antibody and western blotting with anti-VEGF-C antibody. A 30kDa band was observed under native and denaturation conditions ( Figure 2F) . A competitive sandwich ELISA was performed and demonstrated that 98.61±3.8% of VEGF-C in the cornea is in the bound form while 1.5±0.9% is in the free form (n=5, Figure 2G ). 57.87±2% of corneal VEGF-C was bound to sVEGFR-3 and 40.7±1.8% to sVEGFR-2 ( Figure 2G ; n=5). sVEGFR-3 had 3 times higher affinity for VEGF-C than sVEGFR-2, consistent with earlier findings 17 ( Figure 2H ).
Corneal injury induces upregulation of membrane VEGFR-3 and VEGF-C
To characterize the cornea's reaction to trauma, we performed suturing of the cornea, which induced development of blood and lymphatic vessels within 10-14 days. sVEGFR-3 and VEGF-C was present at the site of sutures ( Figure 3A ) with a dramatic increase in levels of VEGF-C mRNA (n=5) ( Figure 3B ). Normal corneas expressed only soluble VEGFR-3, while sutured corneas expressed membrane VEGFR-3 ( Figure 3C ). Low levels of soluble VEGFR-3 and higher levels of VEGFR-3 were observed in sutured corneas from day 5 onward (Figure 3C ). In tandem with these findings from trauma-induced lymphaticized corneas, we examined the spontaneously lymphatic corneas of Pax6 +/− mice 29 for the presence of sVEGFR-3. Corneas of Pax6 +/− mice, unlike those of their background strain C57BL/6J, were deficient in sVEGFR-3 mRNA (Supplemental Figure S2 C-D) .
Soluble VEGFR-3 is necessary for corneal alymphaticity
To determine if sVEGFR-3 preserved corneal alymphaticity, we employed RNA knockdown.
shRNA were directed to two targets in the 3' unique intron of sVEGFR-3 (Supplemental Figure   S3A ). Controls included plasmids expressing a shRNA targeting a sequence in the unique
For personal use only. on April 18, 2017. by guest www.bloodjournal.org From carboxyl-terminus region of VEGFR-3 not present in sVEGFR-3 (pshRNA-VEGFR-3) and a scrambled sequence (pshRNA-CTR). Corneal injection of plasmid pshRNA-sVEGFR-3, but not pshRNA-CTR or pshRNA-VEGFR-3, reduced sVEGFR-3 mRNA (Supplemental Figure S3B, C). This increased free VEGF-C in the cornea (Supplemental Figure S3D) , corroborating our hypothesis that sVEGFR-3 mediates VEGF-C sequestration.
pshRNA-sVEGFR-3 injection into cornea led to formation of lymphatic vessels 10 days post-injection (Cornea area 8.73±1.07%, n=10) ( Figure 4A, B) . Interestingly, these corneas also induced blood vessels (cornea area 7.06±1.71%, n=10) ( Figure 4A, C) . A similar pattern of results was observed using small interfering RNA oligos (siRNA) designed for another target site in the unique carboxyl terminal region of sVEGFR-3 (Supplemental Figure S4A-C) . This effect was abolished by injection of anti-VEGF-C antibodies one day prior to pshRNA-sVEGFR-3 treatment, which suppressed both lymphatic and blood vessels ( Figure 4A ). There was a 75% reduction in lymphatic vessel (total area 2.16±0.46% (P< 0.01, n=10) ( Figure 4B ) and a 56% reduction of blood vessel (total area 3.08±0.44%, P< 0.01, n=10) area ( Figure 4C ).
Corneal injection with pshRNA-sVEGFR-3 induced increased expression of membrane VEGFR-3 ( Figure 4D ) and phosphorylation of VEGFR-3 ( Figure 4E ). Soluble VEGFR-3 is present after control shRNA treatment but membrane VEGFR-3 is expressed after pshRNAsVEGFR-3 treatment ( Figure 4F ). This suggests that ablation of sVEGFR-3 and the subsequent VEGF-C surge leads to upregulation of membrane VEGFR-3, with unbound VEGF-C binding to and inducing membrane-bound VEGFR-3 signal transduction.
Overexpression of soluble VEGFR-3 suppresses growth of lymphatic and blood vessels
To determine if sVEGFR-3 overexpression could preserve corneal alymphaticity and avascularity, a plasmid over-expressing sVEGFR-3 (pCMV.sVEGFR-3) was injected one day 1 3 before suturing the cornea. This injection suppressed the growth of lymphatic and blood vessels compared to control pCMV (pCMV.CTR). Corneas were harvested 10 days after injection.
Sutured corneas injected with pCMV.CTR had mean fractional lymphatic area of 18.55±2.54%, (n=10) ( Figure 5A ) and mean fractional hemangiogenic area of 24.92±2.69% (n=10) ( Figure   5B ). Injection with pCMV.sVEGFR-3 into sutured cornea led to 58% decrease in lymphatic area (7.78 ± 2.24%, P< 0.01, n=10) and a 31% decrease in blood vessel area (17.20 ± 2.37%, P< 0.01, n=10) ( Figure 5A, B) .
Overexpression of soluble VEGFR-3 results in increased corneal transplant survival
To determine if these effects were clinically relevant, penetrating corneal transplantation was performed using C57BL/6 mice as graft donors and BALB/c as graft recipients ( Figure 5C, D) .
Subconjunctival injection of plasmid over-expressing sVEGFR-3 (pCMV.sVEGFR-3) and control empty pCMV the day of keratoplasty and postoperatively at 1, 2, 3, and 4 weeks in BALB/c recipient mice ( Figure 5E ). Graft protection was 40.0% in sVEGFR3 group and 8.3% in empty pCMV group (p=0.032, Figure 5F ).
Soluble VEGFR-3 suppressed hemangiogenesis through the blocking of VEGF-C induced VEGFR-2 phosphorylation
To determine why soluble VEGFR-3 suppressed hemangiogenesis, we examined whether endogenous soluble or membrane VEGFR-3 heterodimerizes with VEGFR-2 by immunoprecipitation of VEGFR-2. After the immunoprecipitation of VEGFR-2, soluble or membrane VEGFR3 was not detected by western blotting with anti N-terminal VEGFR-3 antibody ( Figure 6A ). Next, we tested whether recombinant soluble VEGFR-3 could inhibit VEGF-A induced VEGFR-2 phosphorylation. We found recombinant soluble VEGFR-3 did not inhibit VEGFR-2 phosphorylation even at a 25-fold higher concentration than VEGF-A (Figure 1  4   6B ). Finally, we tested whether soluble VEGFR-3 inhibits VEGF-C induced VEGFR-2 phosphorylation. We found recombinant soluble VEGFR-3 inhibited VEGFR-2 phosphorylation mediated by VEGF-C ( Figure 6C ). These data indicate soluble VEGFR-3 suppressed hemangiogenesis through the blocking of VEGF-C induced VEGFR-2 phosphorylation, but not through heterodimerization or blockade of VEGF-A.
Discussion
We demonstrate that expression of endogenous soluble VEGFR-3 plays a key role in maintaining an alymphatic cornea, which, in turn, establishes the immune privilege of the cornea. The protein, similar to and along with the previously described soluble VEGFR-2 11 , acts as an endogenous antagonist by serving as a decoy receptor for free monomeric VEGF-C, preventing lymphangiogenesis, consistent with previous findings that blockade of membranebound VEGFR-3 suppressed dendritic cell trafficking and rejection of corneal transplants 30 . The binding of VEGF-C to VEGFR-3 is well-established, and its signaling through membrane-bound VEGFR-3 is important for lymphangiogenesis, 15, 31 spontaneous lymphangiogenesis is present in mice with a destrin mutation, which is inhibited with an anti-VEGFR-3 antibody. 32 The previous work relied on antibodies targeting solely the N-terminal VEGFR-3 and was not able to distinguish the activity or presence of the soluble vs membrane isoforms.
Lymphangiogenesis and angiogenesis occur in concert. Previously VEGF-C has been demonstrated to crosstalk between VEGFR-3 and VEGFR-2, though the signaling is not well understood 16, 33 . Here our data directly demonstrates that upregulation or inhibition of VEGF-C via the presence of soluble VEGFR-3 directly controls signaling through VEGFR-3 and VEGFR-2, influencing lymphatic and blood vessel growth or inhibition.
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VEGF-C is an essential chemotactic and survival factor during lymphangiogenesis 5 . Proinflammatory cytokines induce the VEGF-C messenger RNA transcription, presumably through NF-ĸβ-mediated promoter activation, suggesting a regulatory role in lymphatic vessel growth during inflammation. 34 The strong expression of natural soluble VEGFR-3 in the corneal epithelium provides a defense mechanism for the cornea to counter inflammatory stimuli induced by eye exposure to foreign particles, allergens, microorganisms, and mechanical rubbing.
Over-expression of the extracellular domain of VEGFR-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. 35 A fusion protein consisting of three extracellular domains of VEGFR-3 tagged to the IgG Fc domain inhibits fetal lymphangiogenesis and regression of already formed lymphatic vessels. 36 We believe vision-threatening injuries and infections of the cornea shift VEGFR-3 splicing mechanism towards the membrane-bound 
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